EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Making the leap from technique to treatment — genetic engineering is paving the way for more efficient phage therapy

Jessica M Lewis, Joshua Williams, Antonia P Sagona iD

Biochemical Society Transactions · 2024

DOI: 10.1042/bst20231289 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, 2024. Verfasst von Jessica M Lewis und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, University of Warwick, Coventry, U.K. Hauptthemen laut MEDLINE: Phage Therapy, Bacteriophages, Genetic Engineering. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bacteriophages (phages) are viruses specific to bacteria that target them with great efficiency and specificity. Phages were first studied for their antibacterial potential in the early twentieth century; however, their use was largely eclipsed by the popularity of antibiotics. Given the surge of antimicrobial-resistant strains worldwide, there has been a renaissance in harnessing phages as therapeutics once more. One of the key advantages of phages is their amenability to modification, allowing the generation of numerous derivatives optimised for specific functions depending on the modification. These enhanced derivatives could display higher infectivity, expanded host range or greater affinity to human tissues, where some bacterial species exert their pathogenesis. Despite this, there has been a noticeable discrepancy between the generation of derivatives in vitro and their clinical application in vivo. In most instances, phage therapy is only used on a compassionate-use basis, where all other treatment options have been exhausted. A lack of clinical trials and numerous regulatory hurdles hamper the progress of phage therapy and in turn, the engineered variants, in becoming widely used in the clinic. In this review, we outline the various types of modifications enacted upon phages and how these modifications contribute to their enhanced bactericidal function compared with wild-type phages. We also discuss the nascent progress of genetically modified phages in clinical trials along with the current issues these are confronted with, to validate it as a therapy in the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phage TherapyBacteriophagesGenetic EngineeringHumansBacterial InfectionsBacteriaAnimalsAnti-Bacterial Agents

Stichwörter der Autor:innen

clinical trialshost range expansionphage engineeringphage therapyphage weaponisation

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • School of Life Sciences, University of Warwick, Coventry, U.K.

ORCID-Profile: Antonia P Sagona

Zitieren

APA

Lewis, J. M., Williams, J., & Sagona, A. P. (2024). Making the leap from technique to treatment — genetic engineering is paving the way for more efficient phage therapy. Biochemical Society Transactions. https://doi.org/10.1042/bst20231289

Vancouver

Lewis JM, Williams J, Sagona AP. Making the leap from technique to treatment — genetic engineering is paving the way for more efficient phage therapy. Biochemical Society Transactions. 2024. doi:10.1042/bst20231289

BibTeX
@article{Lewis2024,
  author = {Lewis, Jessica M and Williams, Joshua and Sagona, Antonia P},
  title = {Making the leap from technique to treatment — genetic engineering is paving the way for more efficient phage therapy},
  journal = {Biochemical Society Transactions},
  year = {2024},
  doi = {10.1042/bst20231289}
}
Kostenlos starten →